Latest & greatest articles for pregnancy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregnancy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregnancy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregnancy

1. Pregnancy and Maternal Obesity Part 1: Pre-conception and Prenatal Care

Pregnancy and Maternal Obesity Part 1: Pre-conception and Prenatal Care Pregnancy and Maternal Obesity Part 1: Pre-conception and Prenatal Care Toggle navigation Toggle search Keyword search language Keyword search Pregnancy and Maternal Obesity Part 1: Pre-conception and Prenatal Care If you are not automatically redirected to the JOGC site within 15 seconds, please click the link above. No information available ID Access The Society of Obstetricians and Gynaecologists of Canada (SOGC) {1} {1

2019 Society of Obstetricians and Gynaecologists of Canada

2. Pregnancy and Maternal Obesity Part 2: Team Planning for Delivery and Postpartum Care

Pregnancy and Maternal Obesity Part 2: Team Planning for Delivery and Postpartum Care Pregnancy and Maternal Obesity Part 2: Team Planning for Delivery and Postpartum Care Toggle navigation Toggle search Keyword search language Keyword search Pregnancy and Maternal Obesity Part 2: Team Planning for Delivery and Postpartum Care If you are not automatically redirected to the JOGC site within 15 seconds, please click the link above. No information available ID Access The Society of Obstetricians

2019 Society of Obstetricians and Gynaecologists of Canada

3. Pregnancy and Renal Disease

Pregnancy and Renal Disease Clinical Practice Guideline Pregnancy and Renal Disease Authors: Kate Wiles - Chair NIHR Doctoral Research Fellow in Obstetric Nephrology, Guy’s and St. Thomas’ NHS Foundation Trust and King's College London Lucy Chappell Professor of Obstetrics, King's College London and Consultant Obstetrician, Guy’s and St. Thomas’ NHS Foundation Trust Katherine Clark Specialist Midwife, King’s College Hospital NHS Foundation Trust Louise Elman Expert Patient Matt Hall Consultant (...) Nephrologist, King’s College Hospital NHS Foundation Trust and King’s College London Final Version: September 2019 Review Date: September 2024 Renal Association Clinical Practice Guideline Pregnancy and Renal Disease – September 2019 2 Endorsements The National Institute for Health and Care Excellence (NICE) has accredited the process used by the Renal Association to produce its Clinical Practice Guidelines. Accreditation is valid for 5 years from January 2017. More information on accreditation can

2019 Renal Association

4. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer

Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer Current guidelines recommend that women delay pregnancy for 6 to 12 months after the receipt of radioactive iodine treatment (RAIT) following thyroidectomy for differentiated thyroid carcinoma. Although concerns exist regarding the risks associated with pregnancy after RAIT, no large-scale study, to date, has investigated the association between RAIT and pregnancy (...) outcomes.To investigate whether RAIT was associated with increases in adverse pregnancy outcomes among South Korean women who received RAIT after thyroidectomy for thyroid cancer and to evaluate the appropriate interval between RAIT and conception.This population-based cohort study used the Health Insurance Review and Assessment database of South Korea to identify a total of 111 459 women of childbearing age (20-49 years) who underwent thyroidectomy for the treatment of differentiated thyroid carcinoma

2019 EvidenceUpdates

5. Continuous Glucose Monitoring in Pregnancy

Continuous Glucose Monitoring in Pregnancy Continuous Glucose Monitoring in Pregnancy - Health Technology Wales > Continuous Glucose Monitoring in Pregnancy Continuous Glucose Monitoring in Pregnancy Topic Status Incomplete Continuous glucose monitoring systems for managing diabetes in pregnant women. Summary Health Technology Wales researchers searched for evidence on the clinical and cost effectiveness of continuous glucose monitoring as an aid to managing diabetes for pregnant women. Based

2019 Health Technology Wales

6. Termination of pregnancy

Termination of pregnancy Maternity and Neonatal C linical G uideline Queensland Health Termination of pregnancy Queensland Clinical Guideline: Termination of pregnancy Refer to online version, destroy printed copies after use Page 2 of 32 Document title: Termination of pregnancy Publication date: April 2013 Document number: MN13.21-V3-R19 Document supplement: The document supplement is integral to and should be read in conjunction with this guideline. Amendments: Full version history (...) : Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au, phone (07) 3234 1479. Queensland Clinical Guideline: Termination of pregnancy Refer to online version, destroy printed copies after use Page 3 of 32 Flow Chart: Summary of termination of pregnancy Queensland Clinical Guidelines: Summary of termination of pregnancy Flowchart: F13.21-1-V3-R19 Legal requirements ToP Act 2018 Less than or equal to 22+0 weeks · A medical practitioner may perform

2019 Queensland Health

7. Regimens of vitamin D supplementation for women during pregnancy. (PubMed)

Regimens of vitamin D supplementation for women during pregnancy. Vitamin D deficiency during pregnancy increases the risk of pre-eclampsia, gestational diabetes, preterm birth, and low birthweight. In a previous Cochrane Review we found that supplementing pregnant women with vitamin D alone compared to no vitamin D supplementation may reduce the risk of pre-eclampsia, gestational diabetes, and low birthweight and may increase the risk of preterm births if it is combined with calcium. However (...) the effects of different vitamin D regimens are not yet clear.To assess the effects and safety of different regimens of vitamin D supplementation alone or in combination with calcium or other vitamins, minerals or nutrients during pregnancy, specifically doses of 601 international units per day (IU/d) or more versus 600 IU/d or less; and 4000 IU/d or more versus 3999 IU/d or less.We searched the Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials

2019 Cochrane

8. Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines

Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Buprenorphine (...) for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines Last updated: May 9, 2019 Project Number: RC1111-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of various buprenorphine or buprenorphine-naloxone formulations versus other buprenorphine formulations for the treatment of opioid use disorders during pregnancy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Withdrawal Management and Treatment of Crystal Methamphetamine Addiction in Pregnancy: A Review of Clinical Effectiveness and Guidelines

Withdrawal Management and Treatment of Crystal Methamphetamine Addiction in Pregnancy: A Review of Clinical Effectiveness and Guidelines Withdrawal Management and Treatment of Crystal Methamphetamine Addiction in Pregnancy: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Withdrawal Management and Treatment of Crystal Methamphetamine Addiction in Pregnancy: A Review of Clinical Effectiveness and Guidelines Withdrawal Management and Treatment of Crystal (...) Methamphetamine Addiction in Pregnancy: A Review of Clinical Effectiveness and Guidelines Last updated: June 17, 2019 Project Number: RC1130-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of interventions for the withdrawal management or treatment of persons who are pregnant and addicted to crystal methamphetamine? What are the evidence-based guidelines regarding withdrawal management

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Pregnancy Testing for Patients Requiring Diagnostic Imaging or Surgery in the Emergency Department: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Pregnancy Testing for Patients Requiring Diagnostic Imaging or Surgery in the Emergency Department: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Pregnancy Testing for Patients Requiring Diagnostic Imaging or Surgery in the Emergency Department: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Pregnancy Testing for Patients Requiring Diagnostic Imaging or Surgery in the Emergency Department: Clinical Effectiveness, Cost (...) -Effectiveness, and Guidelines Pregnancy Testing for Patients Requiring Diagnostic Imaging or Surgery in the Emergency Department: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 28, 2019 Project Number: RB1345-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of performing a pregnancy test prior to diagnostic imaging or surgery in the emergency department setting? What

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Caesarean Delivery for Pregnancies in the First Stage of Labor: Clinical Effectiveness and Guidelines

Caesarean Delivery for Pregnancies in the First Stage of Labor: Clinical Effectiveness and Guidelines Caesarean Delivery for Pregnancies in the First Stage of Labor: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Caesarean Delivery for Pregnancies in the First Stage of Labor: Clinical Effectiveness and Guidelines Caesarean Delivery for Pregnancies in the First Stage of Labor: Clinical Effectiveness and Guidelines Last updated: September 9, 2019 Project Number (...) : RB1393-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What are the benefits and harms of caesarean delivery for Robson group 1 pregnancies with failure to progress in the latent phase of labor? What are the benefits and harms of caesarean delivery for Robson group 2A pregnancies with failure to progress in the latent phase of labor? What are the benefits and harms of caesarean delivery for Robson group 1 pregnancies with failure

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Caesarean Delivery for Pregnancies in the Second Stage of Labor: Clinical Effectiveness and Guidelines

Caesarean Delivery for Pregnancies in the Second Stage of Labor: Clinical Effectiveness and Guidelines Caesarean Delivery for Pregnancies in the Second Stage of Labor: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Caesarean Delivery for Pregnancies in the Second Stage of Labor: Clinical Effectiveness and Guidelines Caesarean Delivery for Pregnancies in the Second Stage of Labor: Clinical Effectiveness and Guidelines Last updated: September 16, 2019 Project (...) Number: RB1394-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What are the benefits and harms of caesarean delivery for Robson group 1 pregnancies with failure to progress in the second stage of labour? What are the benefits and harms of caesarean delivery for Robson group 2A pregnancies with failure to progress in the second stage of labour? What are the evidence-based guidelines regarding the use of caesarean delivery for Robson

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy

Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login (...) keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy Scott Dunkley, Julie A Curtin, Anthony J Marren, Robert P Heavener, Simon McRae and Jennifer L Curnow Med J Aust 2019; 210 (7): . || doi: 10.5694/mja2.50123 Published online: 15 April 2019 Topics Abstract Introduction: There have been significant advances in the understanding of the management of inherited bleeding disorders

2019 MJA Clinical Guidelines

14. Non-invasive prenatal testing to determine the risk of autosomal trisomies 13, 18 and 21 in high-risk pregnancies

Non-invasive prenatal testing to determine the risk of autosomal trisomies 13, 18 and 21 in high-risk pregnancies 1 Translation of the key statement of the final report S16-06 Nicht invasive Pränataldiagnostik (NIPD) zur Bestimmung des Risikos autosomaler Trisomien 13, 18 und 21 bei Risikoschwangerschaften (Version 1.0; Status: 30 April 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-06 Non-invasive prenatal testing (NIPT) to determine the risk of autosomal trisomies 13, 18 and 21 in high-risk pregnancies 1 Extract of final report S16-06 Version 1.0 Non-invasive prenatal testing (NIPT) 30 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Non-invasive

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

15. Fingolimod (Gilenya): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception

Fingolimod (Gilenya): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital (...) services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception Fingolimod is associated with an increased risk of major congenital malformations including cardiac, renal, and musculoskeletal defects, when

2019 MHRA Drug Safety Update

16. Association of High-Dose Vitamin D Supplementation During Pregnancy With the Risk of Enamel Defects in Offspring: A 6-Year Follow-up of a Randomized Clinical Trial

Association of High-Dose Vitamin D Supplementation During Pregnancy With the Risk of Enamel Defects in Offspring: A 6-Year Follow-up of a Randomized Clinical Trial Enamel defects of developmental origin affect up to 38% of schoolchildren and is recognized as a global public health challenge. The impaired enamel formation results in pain owing to hypersensitivity, posteruptive breakdowns, rapid caries progression, and extractions in some cases. The etiology is unknown; therefore, prevention (...) is currently not possible.To assess the association of a high-dose vitamin D supplementation in pregnant women with enamel defects and caries in their offspring.Post hoc analysis of a double-blind, single-center, randomized clinical trial, the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort (COPSAC2010). Enrollment began March 2009 and included 623 women recruited at 24 weeks of pregnancy and 588 of their children. A dental examination was completed at age 6 years in 496 of 588 children

2019 EvidenceUpdates

17. UK guidelines on the management of iron deficiency in pregnancy

UK guidelines on the management of iron deficiency in pregnancy UK guidelines on the management of iron deficiency in pregnancy - Pavord - - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term Guideline Free Access UK guidelines on the management of iron deficiency in pregnancy Department of Haematology, Oxford University Hospitals, Oxford, UK Women's Health Research (...) . I have read and accept the Wiley Online Library Terms and Conditions of Use. Shareable Link Use the link below to share a full-text version of this article with your friends and colleagues. Copy URL Share a link Share on ). The prevalence of anaemia in pregnancy remains high. In order to minimise adverse outcomes, including use of blood transfusion, further research is required to define optimal management, as many current recommendations are not supported by high quality evidence. Methods

2019 British Committee for Standards in Haematology

18. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. (PubMed)

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Hypertension is the most common medical disorder in pregnancy, complicating one in ten pregnancies. Treatment of severely increased blood pressure is widely recommended to reduce the risk for maternal complications. Regimens for the acute treatment of severe hypertension typically include intravenous medications. Although

2019 Lancet Controlled trial quality: predicted high

19. Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. (PubMed)

Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. The hypertensive disorders of pregnancy include pre-eclampsia, gestational hypertension, chronic hypertension, and undefined hypertension. Pre-eclampsia is considerably more prevalent in low-income than in high-income countries. One possible explanation for this discrepancy is dietary differences, particularly calcium deficiency. Calcium supplementation in the second half (...) of pregnancy reduces the serious consequences of pre-eclampsia, but has limited effect on the overall risk of pre-eclampsia. It is important to establish whether calcium supplementation before, and in early pregnancy (before 20 weeks' gestation) has added benefit. Such evidence could count towards justification of population-level interventions to improve dietary calcium intake, including fortification of staple foods with calcium, especially in contexts where dietary calcium intake is known

2019 Cochrane

20. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. (PubMed)

Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Intrahepatic cholestasis of pregnancy, characterised by maternal pruritus and increased serum bile acid concentrations, is associated with increased rates of stillbirth, preterm birth, and neonatal unit admission. Ursodeoxycholic acid is widely used as a treatment without an adequate evidence base. We aimed to evaluate whether ursodeoxycholic acid reduces adverse (...) perinatal outcomes in women with intrahepatic cholestasis of pregnancy.We did a double-blind, multicentre, randomised placebo-controlled trial at 33 hospital maternity units in England and Wales. We recruited women with intrahepatic cholestasis of pregnancy, who were aged 18 years or older and with a gestational age between 20 weeks and 40 weeks and 6 days, with a singleton or twin pregnancy and no known lethal fetal anomaly. Participants were randomly assigned 1:1 to ursodeoxycholic acid or placebo

2019 Lancet Controlled trial quality: predicted high